Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project

Susan M. Chang, Ian F Parney, Michael McDermott, Fred G. Barker, Meic H. Schmidt, Wei Huang, Edward R. Laws, Kevin O. Lillehei, Mark Bernstein, Henry Brem, Andrew E. Sloan, Mitchel Berger

Research output: Contribution to journalArticle

192 Citations (Scopus)

Abstract

Object. In many new clinical trials of patients with malignant gliomas surgical intervention is incorporated as an integral part of tumor-directed interstitial therapies such as gene therapy, biodegradable wafer placement, and immunotherapy. Assessment of toxicity is a major component of evaluating these novel therapeutic interventions, but this must be done in light of known complication rates of craniotomy for tumor resection. Factors predicting neurological outcome would also be helpful for patient selection for surgically based clinical trials. Methods. The Glioma Outcome Project is a prospectively compiled database containing information on 788 patients with malignant gliomas that captured clinical practice patterns and patient outcomes. Patients in this series who underwent their first or second craniotomy were analyzed separately for presenting symptoms, tumor and patient characteristics, and perioperative complications. Preoperative and intraoperative factors possibly related to neurological outcome were evaluated. There were 408 patients who underwent first craniotomies (C1 group) and 91 patients who underwent second ones (C2 group). Both groups had similar patient and tumor characteristics except for their median age (55 years in the C1 group compared with 50 years in the C2 group; p = 0.006). Headache was more common at presentation in the C1 group, whereas papilledema and an altered level of consciousness were more common at presentation in patients undergoing second surgeries. Perioperative complications occurred in 24% of patients in the C1 group and 33% of patients in the C2 group (p = 0.1). Most patients were the same or better neurologically after surgery, but more patients in the C2 group (18%) displayed a worsened neurological status than those in the C1 group (8%; p = 0.007). The Karnofsky Performance Scale score and, in patients in the C2 group, tumor size were important neurological outcome predictors. Regional complications occurred at similar rates in both groups. Systemic infections occurred more frequently in the C2 group (4.4 compared with 0%; p < 0.0001) as did depression (20 compared with 11%; p = 0.02). The perioperative mortality rate was 1.5% for the C1 group and 2.2% for the C2 group (p = not significant). The median length of the hospital stay was 4 days in each group. Conclusions. Perioperative complications occur slightly more often following a second craniotomy for malignant glioma than after the first craniotomy. This should be considered when evaluating toxicities from intraoperative local therapies requiring craniotomy. Nevertheless, most patients are neurologically stable or improved after either their first or second craniotomy. This data set may serve as a benchmark for neurosurgeons and others in a discussion of operative risks in patients with malignant gliomas.

Original languageEnglish (US)
Pages (from-to)1175-1181
Number of pages7
JournalJournal of Neurosurgery
Volume98
Issue number6
StatePublished - Jun 1 2003
Externally publishedYes

Fingerprint

Craniotomy
Glioma
Neoplasms
Length of Stay
Clinical Trials
Physicians' Practice Patterns
Consciousness Disorders
Karnofsky Performance Status
Benchmarking
Papilledema
Genetic Therapy
Immunotherapy
Patient Selection

Keywords

  • Craniotomy
  • Malignant glioma
  • Outcome
  • Postoperative complication

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. / Chang, Susan M.; Parney, Ian F; McDermott, Michael; Barker, Fred G.; Schmidt, Meic H.; Huang, Wei; Laws, Edward R.; Lillehei, Kevin O.; Bernstein, Mark; Brem, Henry; Sloan, Andrew E.; Berger, Mitchel.

In: Journal of Neurosurgery, Vol. 98, No. 6, 01.06.2003, p. 1175-1181.

Research output: Contribution to journalArticle

Chang, SM, Parney, IF, McDermott, M, Barker, FG, Schmidt, MH, Huang, W, Laws, ER, Lillehei, KO, Bernstein, M, Brem, H, Sloan, AE & Berger, M 2003, 'Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project', Journal of Neurosurgery, vol. 98, no. 6, pp. 1175-1181.
Chang, Susan M. ; Parney, Ian F ; McDermott, Michael ; Barker, Fred G. ; Schmidt, Meic H. ; Huang, Wei ; Laws, Edward R. ; Lillehei, Kevin O. ; Bernstein, Mark ; Brem, Henry ; Sloan, Andrew E. ; Berger, Mitchel. / Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project. In: Journal of Neurosurgery. 2003 ; Vol. 98, No. 6. pp. 1175-1181.
@article{9e025a2bb24847b894994647b420f721,
title = "Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project",
abstract = "Object. In many new clinical trials of patients with malignant gliomas surgical intervention is incorporated as an integral part of tumor-directed interstitial therapies such as gene therapy, biodegradable wafer placement, and immunotherapy. Assessment of toxicity is a major component of evaluating these novel therapeutic interventions, but this must be done in light of known complication rates of craniotomy for tumor resection. Factors predicting neurological outcome would also be helpful for patient selection for surgically based clinical trials. Methods. The Glioma Outcome Project is a prospectively compiled database containing information on 788 patients with malignant gliomas that captured clinical practice patterns and patient outcomes. Patients in this series who underwent their first or second craniotomy were analyzed separately for presenting symptoms, tumor and patient characteristics, and perioperative complications. Preoperative and intraoperative factors possibly related to neurological outcome were evaluated. There were 408 patients who underwent first craniotomies (C1 group) and 91 patients who underwent second ones (C2 group). Both groups had similar patient and tumor characteristics except for their median age (55 years in the C1 group compared with 50 years in the C2 group; p = 0.006). Headache was more common at presentation in the C1 group, whereas papilledema and an altered level of consciousness were more common at presentation in patients undergoing second surgeries. Perioperative complications occurred in 24{\%} of patients in the C1 group and 33{\%} of patients in the C2 group (p = 0.1). Most patients were the same or better neurologically after surgery, but more patients in the C2 group (18{\%}) displayed a worsened neurological status than those in the C1 group (8{\%}; p = 0.007). The Karnofsky Performance Scale score and, in patients in the C2 group, tumor size were important neurological outcome predictors. Regional complications occurred at similar rates in both groups. Systemic infections occurred more frequently in the C2 group (4.4 compared with 0{\%}; p < 0.0001) as did depression (20 compared with 11{\%}; p = 0.02). The perioperative mortality rate was 1.5{\%} for the C1 group and 2.2{\%} for the C2 group (p = not significant). The median length of the hospital stay was 4 days in each group. Conclusions. Perioperative complications occur slightly more often following a second craniotomy for malignant glioma than after the first craniotomy. This should be considered when evaluating toxicities from intraoperative local therapies requiring craniotomy. Nevertheless, most patients are neurologically stable or improved after either their first or second craniotomy. This data set may serve as a benchmark for neurosurgeons and others in a discussion of operative risks in patients with malignant gliomas.",
keywords = "Craniotomy, Malignant glioma, Outcome, Postoperative complication",
author = "Chang, {Susan M.} and Parney, {Ian F} and Michael McDermott and Barker, {Fred G.} and Schmidt, {Meic H.} and Wei Huang and Laws, {Edward R.} and Lillehei, {Kevin O.} and Mark Bernstein and Henry Brem and Sloan, {Andrew E.} and Mitchel Berger",
year = "2003",
month = "6",
day = "1",
language = "English (US)",
volume = "98",
pages = "1175--1181",
journal = "Journal of Neurosurgery",
issn = "0022-3085",
publisher = "American Association of Neurological Surgeons",
number = "6",

}

TY - JOUR

T1 - Perioperative complications and neurological outcomes of first and second craniotomies among patients enrolled in the Glioma Outcome Project

AU - Chang, Susan M.

AU - Parney, Ian F

AU - McDermott, Michael

AU - Barker, Fred G.

AU - Schmidt, Meic H.

AU - Huang, Wei

AU - Laws, Edward R.

AU - Lillehei, Kevin O.

AU - Bernstein, Mark

AU - Brem, Henry

AU - Sloan, Andrew E.

AU - Berger, Mitchel

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Object. In many new clinical trials of patients with malignant gliomas surgical intervention is incorporated as an integral part of tumor-directed interstitial therapies such as gene therapy, biodegradable wafer placement, and immunotherapy. Assessment of toxicity is a major component of evaluating these novel therapeutic interventions, but this must be done in light of known complication rates of craniotomy for tumor resection. Factors predicting neurological outcome would also be helpful for patient selection for surgically based clinical trials. Methods. The Glioma Outcome Project is a prospectively compiled database containing information on 788 patients with malignant gliomas that captured clinical practice patterns and patient outcomes. Patients in this series who underwent their first or second craniotomy were analyzed separately for presenting symptoms, tumor and patient characteristics, and perioperative complications. Preoperative and intraoperative factors possibly related to neurological outcome were evaluated. There were 408 patients who underwent first craniotomies (C1 group) and 91 patients who underwent second ones (C2 group). Both groups had similar patient and tumor characteristics except for their median age (55 years in the C1 group compared with 50 years in the C2 group; p = 0.006). Headache was more common at presentation in the C1 group, whereas papilledema and an altered level of consciousness were more common at presentation in patients undergoing second surgeries. Perioperative complications occurred in 24% of patients in the C1 group and 33% of patients in the C2 group (p = 0.1). Most patients were the same or better neurologically after surgery, but more patients in the C2 group (18%) displayed a worsened neurological status than those in the C1 group (8%; p = 0.007). The Karnofsky Performance Scale score and, in patients in the C2 group, tumor size were important neurological outcome predictors. Regional complications occurred at similar rates in both groups. Systemic infections occurred more frequently in the C2 group (4.4 compared with 0%; p < 0.0001) as did depression (20 compared with 11%; p = 0.02). The perioperative mortality rate was 1.5% for the C1 group and 2.2% for the C2 group (p = not significant). The median length of the hospital stay was 4 days in each group. Conclusions. Perioperative complications occur slightly more often following a second craniotomy for malignant glioma than after the first craniotomy. This should be considered when evaluating toxicities from intraoperative local therapies requiring craniotomy. Nevertheless, most patients are neurologically stable or improved after either their first or second craniotomy. This data set may serve as a benchmark for neurosurgeons and others in a discussion of operative risks in patients with malignant gliomas.

AB - Object. In many new clinical trials of patients with malignant gliomas surgical intervention is incorporated as an integral part of tumor-directed interstitial therapies such as gene therapy, biodegradable wafer placement, and immunotherapy. Assessment of toxicity is a major component of evaluating these novel therapeutic interventions, but this must be done in light of known complication rates of craniotomy for tumor resection. Factors predicting neurological outcome would also be helpful for patient selection for surgically based clinical trials. Methods. The Glioma Outcome Project is a prospectively compiled database containing information on 788 patients with malignant gliomas that captured clinical practice patterns and patient outcomes. Patients in this series who underwent their first or second craniotomy were analyzed separately for presenting symptoms, tumor and patient characteristics, and perioperative complications. Preoperative and intraoperative factors possibly related to neurological outcome were evaluated. There were 408 patients who underwent first craniotomies (C1 group) and 91 patients who underwent second ones (C2 group). Both groups had similar patient and tumor characteristics except for their median age (55 years in the C1 group compared with 50 years in the C2 group; p = 0.006). Headache was more common at presentation in the C1 group, whereas papilledema and an altered level of consciousness were more common at presentation in patients undergoing second surgeries. Perioperative complications occurred in 24% of patients in the C1 group and 33% of patients in the C2 group (p = 0.1). Most patients were the same or better neurologically after surgery, but more patients in the C2 group (18%) displayed a worsened neurological status than those in the C1 group (8%; p = 0.007). The Karnofsky Performance Scale score and, in patients in the C2 group, tumor size were important neurological outcome predictors. Regional complications occurred at similar rates in both groups. Systemic infections occurred more frequently in the C2 group (4.4 compared with 0%; p < 0.0001) as did depression (20 compared with 11%; p = 0.02). The perioperative mortality rate was 1.5% for the C1 group and 2.2% for the C2 group (p = not significant). The median length of the hospital stay was 4 days in each group. Conclusions. Perioperative complications occur slightly more often following a second craniotomy for malignant glioma than after the first craniotomy. This should be considered when evaluating toxicities from intraoperative local therapies requiring craniotomy. Nevertheless, most patients are neurologically stable or improved after either their first or second craniotomy. This data set may serve as a benchmark for neurosurgeons and others in a discussion of operative risks in patients with malignant gliomas.

KW - Craniotomy

KW - Malignant glioma

KW - Outcome

KW - Postoperative complication

UR - http://www.scopus.com/inward/record.url?scp=0038188507&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038188507&partnerID=8YFLogxK

M3 - Article

C2 - 12816260

AN - SCOPUS:0038188507

VL - 98

SP - 1175

EP - 1181

JO - Journal of Neurosurgery

JF - Journal of Neurosurgery

SN - 0022-3085

IS - 6

ER -